EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Latest on Anabolic Agents for Osteoporosis Treatment

Luigi di Filippo, Clifford J Rosen

Endocrinology and Metabolism Clinics of North America · 2024

DOI: 10.1016/j.ecl.2024.08.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism Clinics of North America, 2024. Verfasst von Luigi di Filippo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Endocrine and Metabolic Sciences, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address:…. Hauptthemen laut MEDLINE: Osteoporosis, Anabolic Agents, Bone Density Conservation Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the last decades, novel therapeutics with anabolic bone properties have been developed and are currently used in the management of osteoporosis particularly in patients with high-risk of fragility fractures. These drugs include PTH-Related Analogues, teriparatide and abaloparatide, and the anti-sclerostin agent romosozumab, this latter drug currently approved only in female patients. Their efficacies in preventing fragility fractures are widely demonstrated and their potential serious side effects were progressively downgraded, including risk of malignancies in teriparatide- and cardiovascular events in romosozumab-users, respectively. Further data are warranted about their efficacy in glucocorticoids-induces osteoporosis and fracture healings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoporosisAnabolic AgentsBone Density Conservation AgentsHumansTeriparatideOsteoporotic FracturesAntibodies, MonoclonalParathyroid Hormone-Related Protein

Stichwörter der Autor:innen

AbaloparatideAnabolicsBlosozumabFragility fracturesGlucocorticoidsOsteoporosisRomosozumabTeriparatide

Substanzen

Anabolic AgentsBone Density Conservation AgentsabaloparatideTeriparatideromosozumabAntibodies, MonoclonalParathyroid Hormone-Related Protein

Autor:innen und Institutionen

  • Institute of Endocrine and Metabolic Sciences, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: difilippo.luigi@hsr.it.
  • Center for Clinical and Translational Research, MaineHealth Institute for Research, Scarborough, ME 04074, USA.

Zitieren

APA

di Filippo, L., & Rosen, C. J. (2024). Latest on Anabolic Agents for Osteoporosis Treatment. Endocrinology and Metabolism Clinics of North America. https://doi.org/10.1016/j.ecl.2024.08.003

Vancouver

di Filippo L, Rosen CJ. Latest on Anabolic Agents for Osteoporosis Treatment. Endocrinology and Metabolism Clinics of North America. 2024. doi:10.1016/j.ecl.2024.08.003

BibTeX
@article{diFilippo2024,
  author = {di Filippo, Luigi and Rosen, Clifford J},
  title = {Latest on Anabolic Agents for Osteoporosis Treatment},
  journal = {Endocrinology and Metabolism Clinics of North America},
  year = {2024},
  doi = {10.1016/j.ecl.2024.08.003}
}
Kostenlos starten →